A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus

Inclusion Criteria: * Subject must have a body weight in the range of 40 to 100 kilogram (kg), inclusive, and have a body mass index (BMI) of 18 to 32 kilogram per meter square (kg/m\^2), inclusive, at screening * Subjects eligible for enrollment in this study must qualify as follows: a) must meet Systemic Lupus International Collaborating Clinics (SLICC) criteria for diagnosis of lupus and b) must have at least one non-serologic clinical activity defined by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) within 3 months prior to first study agent administration * Have a positive gene signature score during screening, prior to first administration of study agent * Subjects using allowed pre-existing lupus treatments, if stable for at least 6 weeks prior to the first dose of study medication: 1. oral corticosteroids equivalent to an average dose up to or equal to (\<=) 10 milligram (mg) of prednisone/day 2. use of antimalarials (such as chloroquine or hydroxychloroguine) for at least 8 weeks 3. maximum of 1 non-corticosteroid immunosuppressive drug Exclusion Criteria: * Subject with history or suspected occurrence of drug-induced systemic lupus erythematosus (SLE) * Subject has unstable lupus nephritis and/ or has active Central nervous system (CNS) lupus or history of severe CNS lupus, including but not limited to seizures, psychosis, transverse myelitis, CNS vasculitis and optic neuritis * Major surgery prior to, and, if planned, during and shortly after the study is not eligible * Subject has or has had an acute illness, including a common cold, within 2 weeks prior to the study agent administration or has had a major illness or hospitalization within 4 months prior to the screening visit * Any other inflammatory diseases that might confound the evaluations of efficacy are excluded